Skip navigation

Coenzyme Q-10

What is it?

Coenzyme Q-10 (CoQ-10) is a vitamin-like substance found throughout the body, but especially in the heart, liver, kidney, and pancreas. It is eaten in small amounts in meats and seafood. Coenzyme Q-10 can also be made in a laboratory. It is used as medicine.

Many people use coenzyme Q-10 for treating heart and blood vessel conditions such as congestive heart failure (CHF), chest pain (angina), high blood pressure, and heart problems linked to certain cancer drugs. It is also used for diabetes, gum disease (both taken by mouth and applied directly to the gums), breast cancer, Huntington’s disease, Parkinson’s disease, muscular dystrophy, increasing exercise tolerance, chronic fatigue syndrome (CFS), and Lyme disease. Some people think coenzyme Q-10 will treat hair loss related to taking warfarin (Coumadin), a medication used to slow blood clotting.

Some people also think coenzyme Q-10 might help increase energy. This is because coenzyme Q-10 has a role in producing ATP, a molecule in body cells that functions like a rechargeable battery in the transfer of energy. Coenzyme Q-10 been tried for treating inherited or acquired disorders that limit energy production in the cells of the body (mitochondrial disorders), and for improving exercise performance.

Some people have also used coenzyme Q-10 for strengthening the immune systems of people with HIV/AIDS, male infertility, migraine headache, and counteracting muscle pain sometimes caused by a group of cholesterol-lowering medications called “statins.”

Coenzyme Q-10 has even been tried for increasing life span. This idea got started because coenzyme Q-10 levels are highest in the first 20 years of life. By age 80, coenzyme-Q10 levels can be lower than they were at birth. Some people thought that restoring high levels of coenzyme-Q10 late in life might cause people to live longer. The idea works in bacteria, but not in lab rats. More research is needed to see if this works in people.

It’s not only time that uses up the body’s store of coenzyme Q-10. Smoking does, too.

Coenzyme Q-10 was first identified in 1957. The “Q-10” refers to the chemical make-up of the substance. These days coenzyme Q-10 is used by millions of people in Japan for heart disease, especially congestive heart failure. Coenzyme Q-10 is also used extensively in Europe and Russia. Most of the coenzyme Q-10 used in the US and Canada is supplied by Japanese companies. Coenzyme Q-10 is manufactured by fermenting beets and sugar cane with special strains of yeast.

How effective is it?

Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, Ineffective, and Insufficient Evidence to Rate.

The effectiveness ratings for COENZYME Q-10 are as follows:

Likely effective for...

  • Coenzyme Q-10 deficiency. Taking coenzyme Q-10 by mouth seems to improve symptoms of coenzyme Q-10 deficiency. This is a very rare condition. The symptoms include weakness, fatigue, and seizures.
  • Inherited or acquired disorders that limit energy production in the cells of the body (mitochondrial disorders). Taking coenzyme Q-10 by mouth seems to reduce symptoms of mitochondrial disorders. However, improvement in symptoms is slow. Some people have to take coenzyme Q-10 for six months to get the most benefit.

Possibly effective for...

  • Age-related vision loss (age-related macular degeneration). Taking a specific product containing coenzyme Q-10, acetyl-L-carnitine, and omega-3 fatty acids (Phototrop) by mouth seems to improve vision in people with age-related vision loss.
  • Congestive heart failure (CHF). Some research suggests that heart failure might be linked with low coenzyme Q-10 levels. Although most evidence shows that taking coenzyme Q-10 alone does not help treat heart failure, there is some evidence that it might be helpful when taken in combination with other heart failure medications and treatments.
  • Nerve damage caused by diabetes (diabetic neuropathy). Research shows that taking coenzyme Q-10 improves nerve damage and nerve pain in people with nerve damage caused by diabetes.
  • HIV/AIDS. Taking coenzyme Q-10 by mouth seems to improve immune function in people with HIV/AIDS.
  • An inherited neurological disorder called Huntington’s disease. Ubiquinol, an altered form of coenzyme Q-10, has been granted “Orphan Drug Status” by the U.S. Food and Drug Administration (FDA). This gives the maker of Ubiquinol some financial incentives to study its effectiveness for Huntington’s, a condition that is so rare (affecting less than 200,000 individuals) that pharmaceutical companies might not otherwise invest in developing a drug for it. However, taking coenzyme Q-10 by mouth in doses of 600 mg daily or less does not seem to be effective for slowing the progression of Huntington’s disease.
  • High blood pressure. The majority of research shows that taking coenzyme Q-10 by itself or along with other medications for treating high blood pressure seems to help lower blood pressure. However, one small study suggests that taking coenzyme Q-10 by mouth may not lower blood pressure in people that also have a condition called metabolic syndrome.
  • Blood vessel complications caused by heart bypass surgery. Reduced blood supply during heart or blood vessel surgery can deprive tissue of oxygen. When blood supply returns to this tissue, the tissue can become damaged. There is some evidence that taking coenzyme Q-10 by mouth for a week before heart bypass surgery or blood vessel surgery might help to reduce tissue damage. However, not all research agrees with this finding.
  • A specific type of high blood pressure. Taking coenzyme Q-10 daily appears to lower systolic blood pressure (the top number) in some people with high systolic blood pressure but normal diastolic blood pressure (the bottom number).
  • Migraine headache. Taking coenzyme Q-10 by mouth seems to help prevent migraine headaches. Studies show it can decrease the frequency of headaches by about 30% and the number of days with headache-related nausea by about 45% in adults. Taking coenzyme Q-10 also appears to reduce migraine frequency in children who have low levels of coenzyme Q-10. It can take up to 3 months for significant benefit. However, coenzyme Q-10 does not seem to be effective in treating migraines once they have developed.
  • An inherited muscle disorder called muscular dystrophy. Taking coenzyme Q-10 by mouth seems to improve physical performance in some people with muscular dystrophy
  • Heart attack. When started within 72 hours of a heart attack and taken for one year, coenzyme Q-10 appears to lower the risk of heart-related events, including another heart attack.
  • Parkinson’s disease. Some research shows that taking coenzyme Q-10 supplements might slow decline in people with early Parkinson’s disease. However, taking a coenzyme Q-10 does not seem to improve symptoms in people with mid-stage Parkinson’s disease.
  • Peyronie’s disease (painful erection in men). Research shows that taking coenzyme Q-10 improves erectile function in men with painful erections.

Possibly ineffective for...

  • Alzheimer’s disease. Taking coenzyme Q-10 does not seem to improve mental function in people with Alzheimer’s disease.
  • Neurodegenerative disease called ALS or Lou Gehrid’s disease. Research shows that taking coenzyme Q-10 does not slow the progression of ALS.
  • Cocaine dependence. Taking a combination of coenzyme Q-10 and L-carnitine does not reduce cocaine use.
  • High cholesterol. Some research shows that taking coyenzme Q-10 does not reduce total cholesterol, triglycerides, or low-density lipoprotein (LDL or “bad”) cholesterol, or increase high-density lipoprotein (HDL or “good”) cholesterol. Other research shows that taking coenzyme Q-10 by mouth alone or together with carnitine does not improve cholesterol levels. However, one study in people who can not take statin drugs shows that taking a combination of coenzyme Q-10, berberine, policosanol, red yeast rice, folic acid, and astaxanthin reduces cholesterol levels.
  • Symptoms affecting polio survivors (post-polio syndrome). Research shows that taking coenzyme Q-10 does not improve muscle strength or muscle function in people with post-polio syndrome.

Likely ineffective for...

  • Athletic performance. Taking coenzyme Q-10 by mouth does not improve althetic performance in athletes or non-athletes.

Insufficient evidence to rate effectiveness for...

  • Chest pain (angina). Some early research suggests that taking coenzyme Q-10 by mouth might improve exercise tolerance in patients with angina.
  • Asthma. Some early research suggests that taking a combination of coenzyme Q-10, vitamin E (alpha-tocopherol), and vitamin C in addition to conventional asthma treatment reduces the dosage of drugs needed by people with mild-to-moderate asthma.
  • Breast cancer. Some research in Chinese women suggests that having low blood levels of coenzyme Q-10 is linked to an increased risk of breat cancer. There is preliminary evidence that taking coenzyme Q-10 by mouth might be helpful in advanced breast cancer when used along with surgery and conventional treatment plus other antioxidants and omega-3 and omega-6 fatty acids.
  • Cancer. Research suggests that low coenzyme Q-10 levels are associated with an increased risk of skin cancer. Also, early research suggests that taking coenzyme Q-10 along with other antioxidants increases survival time by 40% in patients with terminal cancer.
  • Heart toxicity caused by chemotherapy drugs. Some research suggests that taking coenzyme Q-10 by mouth may protect the heart in children and adults receiving the chemotherapy drug anthracycline. However, other research suggests that administering coenzyme Q-10 intravenously (by IV) does not provide this benefit.
  • Lung disease called chronic obstructive pulmonary disease (COPD). Early research suggests that taking coenzyme Q-10 improves lung function and exercise tolerance in people with COPD.
  • Cyclic vomiting syndrome. Some early research suggests that taking coenzyme Q-10 might work as well as prescription medications used to treat cyclic vomiting syndrome.
  • Diabetes. Research about the effectiveness of coenzyme Q-10 for diabetes is conflicting. Some research shows that taking coenzyme Q-10 might lower blood sugar levels. However, other research has found no benefit.
  • Weakend and enlarged heart (dilated cardiomyopathy). Early evidence suggests that taking coenzyme Q-10 improves heart function in children with dilated cardiomyopathy.
  • Dry mouth. Early research suggests that taking coenzyme Q-10 (ubiquinol) improves dry mouth.
  • Eye surgery. Research suggests that administering an eye solution containing coenzyme Q-10 and vitamin E increases the speed of nerve regeneration after cataract eye surgery
  • Fibromyalgia. Some early research suggests that taking coenzyme Q-10 along with ginkgo might increase feelings of wellness and overall health, as well as reduce pain in people with fibromyalgia.
  • Uncoordinated movement due to brain damage (cerebellar ataxia). Early research suggests that coenzyme Q-10 improves muscle coordination and movement in people with cerebellar ataxia.
  • Rare inherited disease that causes nerve damage (Friedreich’s ataxia). Early research suggests that taking vitamin E together with coenzyme Q-10 improves coordination, posture, and movement in people with Friedreich’s ataxia.
  • Hearing loss. Research suggests that taking a specific coenzyme Q-10 product (Q-TER) by mouth improves hearing in people with age-related hearing loss. However, combining coenzyme Q-10 with conventional steroid treatments does not improve hearing more than steroid treatment alone.
  • Hepatitis C. Research shows that taking coenzyme Q-10 does not improve liver function in people with hepatitis C who are not responding to conventional treatment.
  • A heart condition called hypertrophic cardiomyopathy. Taking coenzyme Q-10 by mouth seems to decrease the thickness of the heart wall and decrease symptoms of shortness of breath and fatigue in people with hypertrophic cardiomyopathy.
  • Rare genetic disorder called Prader-Willi syndrome. Early research suggests that administering coenzyme Q-10 improves development in children with Prader-Labhart-Willi syndrome. However, it is not clear if these improvements are due to the coenzyme Q-10 or an age-related phenomenon.
  • Male infertility. There is some early evidence that coenzyme Q-10 treatment can improve the movement and density of sperm in men with certain types of infertility. However, other research shows that it does not have a beneficial effect on sperm movement.
  • Inherited diabetes and deafness. There is some early evidence that taking coenzyme Q-10 by mouth might prevent the progression of a rare form of diabetes that is maternally inherited.
  • Gum disease. Applying coenzyme Q-10 to the gums is not effective for treating gum disease. However, there is some early evidence that taking coenzyme Q-10 by mouth might be helpful in treating gum disease.
  • High blood pressure during pregnancy (pre-eclampsia). Pre-eclampsia is a condition that some women develop during pregnancy. Some research shows that women who are at risk have a lower chance of developing the condition if they take coenzyme Q-10 from week 20 of pregnancy until the baby is delivered
  • Prostate cancer. Research shows that taking a combination of vitamin E, selenium, vitamin C, and coenzyme Q-10 does not improve prostate cancer.
  • Kidney failure. Some early research suggests that taking coenzyme Q-10 improves kidney function in people with end-stage kidney disease. However, other research shows that taking coenzyme Q-10 does not improve kidney function.
  • A muscle condition called “statin-induced myopathy.” Statins, a class of drugs used to lower cholesterol, can sometimes cause muscle pain. There is some evidence that taking coenzyme Q-10 might reduce this pain. However, not all evidence has been positive.
  • Hair loss related to use of the warfarin. There is some early evidence that taking coenzyme Q-10 might be helpful for preventing hair loss caused by the blood-thinning drug, warfarin.
  • Wrinkled skin. Early evidence suggests that applying a coenzyme Q-10 cream to the skin improves wrinkled skin.
  • Fatigue.
  • Lyme disease.
  • Other conditions.
More evidence is needed to rate coenzyme Q-10 for these uses.

How does it work?

Return to top
Coenzyme Q-10 is an important vitamin-like substance required for the proper function of many organs and chemical reactions in the body. It helps provide energy to cells. Coenzyme Q-10 also seems to have antioxidant activity. People with certain diseases, such as congestive heart failure, high blood pressure, periodontal disease, Parkinson’s disease, certain muscular diseases, and AIDS, might have lower levels of coenzyme Q-10.

Are there safety concerns?

Return to top
Coenzyme Q-10 is LIKELY SAFE for most adults when taken by mouth or when applied directly to the gums. While most people tolerate coenzyme Q-10 well, it can cause some mild side effects including stomach upset, loss of appetite, nausea, vomiting, and diarrhea. It can cause allergic skin rashes in some people. It also might lower blood pressure, so check your blood pressure carefully if you have very low blood pressure. Dividing the total daily dose by taking smaller amounts two or three times a day instead of a large amount all at once can help reduce side effects.

Coenzyme Q-10 is POSSIBLY SAFE for children when taken by mouth. However, coenzyme Q-10 should not be used in children without medical supervision.

Special precautions & warnings:

Pregnancy and breast-feeding: Coenzyme Q-10 is POSSIBLY SAFE when taken by mouth appropriately during preganancy. Coenzyme Q-10 has been used safely twice daily starting at 20 weeks until delivery. Not enough is known about the use of coenzyme Q-10 during breast-feeding. Stay on the safe side and avoid use.

Chemotherapy: There is some concern that coenzyme Q-10 might lower the effectiveness of some chemotherapy drugs. People undergoing chemotherapy with certain drugs should use coenzyme Q-10 with caution.

High blood pressure or low blood pressure: Coenzyme Q-10 might lower blood pressure. It can increase the effects of medications used to lower blood pressure. Discuss your use of coenzyme Q-10 with your healthcare provider if you have blood pressure problems.

Smoking: Cigarette smoking depletes the amount of coenzyme Q-10 stored by the body.

Surgery: Coenzyme Q-10 might interfere with blood pressure control during and after surgery. Stop using coenzyme Q-10 at least two weeks before a scheduled surgery.

Are there interactions with medications?

Return to top


Be cautious with this combination.

Medications for cancer (Chemotherapy)
Coenzyme Q-10 is an antioxidant. There is some concern that antioxidants might decrease the effectiveness of some medications used for cancers. But it is too soon to know if the interaction occurs.

Medications for high blood pressure (Antihypertensive drugs)
Coenzyme Q-10 seems to decrease blood pressure. Taking coenzyme Q-10 along with medications for high blood pressure might cause your blood pressure to go too low.

Some medications for high blood pressure include captopril (Capoten), enalapril (Vasotec), losartan (Cozaar), valsartan (Diovan), diltiazem (Cardizem), Amlodipine (Norvasc), hydrochlorothiazide (HydroDIURIL), furosemide (Lasix), and many others.

Warfarin (Coumadin)
Warfarin (Coumadin) is used to slow blood clotting while coenzyme Q-10 might increase blood clotting. By helping the blood clot, coenzyme Q-10 might decrease the effectiveness of warfarin (Coumadin) and increase the risk of dangerous clots. Be sure to have your blood checked regularly. The dose of your warfarin (Coumadin) might need to be changed.

Are there interactions with herbs and supplements?

Return to top
Taking coenzyme Q-10 with acacia gum seems to increase the body's absorption of coenzyme Q-10. In theory, this might increase the effects and side effects of coenzyme Q-10.

Coenzyme Q-10 can increase blood levels of beta-carotene. In theory, this might increase the effects and side effects of beta-carotene.

Herbs and supplements that lower blood pressure
Coenzyme Q-10 might decrease blood pressure. Combining coenzyme Q-10 with other herbs and supplements with that lower blood pressure might make blood pressure go too low. Some of these herbs and supplements include andrographis, casein peptides, cat's claw, fish oil, L-arginine, lycium, stinging nettle, theanine, and others.

Omega-3 fatty acids
Combining coenzyme Q-10 with omega-3 fatty acids can reduce blood levels of coenzyme Q-10. In theory, this might reduce the effects of coenzyme Q-10.

Red yeast
Red yeast might reduce coenzyme Q-10 levels. In theory, this might reduce the effects of coenzyme Q-10.

Vitamin A
Coenzyme Q-10 can increase blood levels of vitamin A. In theory, this might increase the effects and side effects of vitamin A.

Vitamin C
Coenzyme Q-10 can increase blood levels of vitamin C. In theory, this might increase the effects and side effects of vitamin C.

Vitamin E
Coenzyme Q-10 can increase blood levels of vitamin E. In theory, this might increase the effects and side effects of vitamin E.

Vitamin K
Coenzyme Q-10 can have effects in the body that are similar to vitamin K, including inhibiting the effects of blood thinning drugs such as warfarin. Taking coenzyme Q-10 with vitamin K might cause additive effects and increase the risk of blood clotting in people taking blood thinning drugs.

Are there interactions with foods?

Return to top
There are no known interactions with foods.

What dose is used?

Return to top
The following doses have been studied in scientific research:

  • For known coenzyme Q-10 deficiency: 150 mg daily.
  • For mitochondrial disorders (mitochondrial encephalomyopathies): 150-160 mg, or 2 mg/kg/day. In some cases, doses may be gradually increased to 3000 mg per day.
  • For heart failure in adults: 100 mg per day divided into 2 or 3 doses.
  • For reducing the risk of future cardiac events in patients with recent myocardial infarction: 120 mg daily in 2 divided doses.
  • For high blood pressure: 120-200 mg per day divided into 2 doses.
  • For isolated systolic hypertension: 60 mg twice daily.
  • For preventing migraine headache: 100 mg three times daily. A dose of 1-3 mg/kg has also been used in pediatric and adolescent patients.
  • For Parkinson’s disease: 300 mg, 600 mg, 1200 mg, and 2400 mg per day in 3-4 divided doses.
  • For HIV/AIDS: 200 mg per day.
  • For infertility in men: 200-300 mg per day.
  • For muscular dystrophy: 100 mg per day.
  • For pre-eclampsia: 100 mg twice daily starting at week 20 of pregnancy until delivery.
Dividing the total daily dose by taking smaller amounts two or three times a day instead of a large amount all at once can help reduce side effects.

Other names

Return to top
Co Q10, Co Q-10, Coenzima Q-10, Co-Enzyme 10, Coenzyme Q 10, Coenzyme Q10, Co-Enzyme Q10, Co-Enzyme Q-10, Co-Q 10, CoQ10, Co-Q10, CoQ-10, Ubidcarenone, Ubidécarénone, Ubiquinone-10.


Return to top
To learn more about how this article was written, please see the Natural Medicines Comprehensive Database methodology.methodology (


Return to top
To see all references for the Coenzyme Q-10 page, please go to

  1. Serra G, Lissoni F, Piemonti C, and et al. Evaluation of coenzyme Q10 in patients with moderate heart failure and chronic stable effort angina. In: Folkers K, Littaru GP, and Yamagami T. Biomedical and clinical aspects of coenzyme Q. Amsterdam: Elsevier Science Publishers;1991.
  2. Singh RB, Khanna HK, and Niaz MA. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in chronic renal failure: discovery of a new role. J Nutr Environ Med 2000;10:281-288.
  3. Young JM, Florkowski CM Molyneux SL McEwan RG Frampton CM George PM. Coenzyme Q10 does not improve simvastatin tolerability in dyslipidemic patients with prior statin-induced myalgia. Circulation 2007;114:II41.
  4. Kelly P, Vasu S Getato M McNurlan M Lawson WE. Coenzyme Q10 improves myopathic pain in statin treated patients (abstr). J Am Coll Cardiol 2005;45:3A.
  5. Digiesi V, Cantini F, and Brodbeck B. Effect of coenzyme Q10 on essential arterial hypertension. Current Therapeutic Research 1990;47:841-845.
  6. Mazzola C, Guffanti EE, Vaccarella A, and et al. Noninvasive assessment of coenzyme Q10 in patients with chronic stable effort angina and moderate heart failure. Current Therapeutic Research 1987;41:923-932.
  7. SA Mortensen, A Kumar P Dolliner KJ Filipiak D Pella U Alehagen G Steurer GP Littarru F Rosenfeldt. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure 2013;15:S1-S20.
  8. Singh, R. B., Wander, G. S., Rastogi, A., Shukla, P. K., Mittal, A., Sharma, J. P., Mehrotra, S. K., Kapoor, R., and Chopra, R. K. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovasc.Drugs Ther. 1998;12:347-353. View abstract.
  9. Ma, A., Zhang, W., and Liu, Z. Effect of protection and repair of injury of mitochondrial membrane- phospholipid on prognosis in patients with dilated cardiomyopathy. Blood Press Suppl 1996;3:53-55. View abstract.
  10. Laaksonen, R., Fogelholm, M., Himberg, J. J., Laakso, J., and Salorinne, Y. Ubiquinone supplementation and exercise capacity in trained young and older men. Eur.J Appl.Physiol Occup.Physiol 1995;72(1-2):95-100. View abstract.
  1. Chen, Y. F., Lin, Y. T., and Wu, S. C. Effectiveness of coenzyme Q10 on myocardial preservation during hypothermic cardioplegic arrest. J Thorac.Cardiovasc.Surg. 1994;107:242-247. View abstract.
  2. Fujimoto, S., Kurihara, N., Hirata, K., and Takeda, T. Effects of coenzyme Q10 administration on pulmonary function and exercise performance in patients with chronic lung diseases. Clin Investig. 1993;71(8 Suppl):S162-S166. View abstract.
  3. Judy, W. V., Stogsdill, W. W., and Folkers, K. Myocardial preservation by therapy with coenzyme Q10 during heart surgery. Clin Investig. 1993;71(8 Suppl):S155-S161. View abstract.
  4. Lampertico, M. and Comis, S. Italian multicenter study on the efficacy and safety of coenzyme Q10 as adjuvant therapy in heart failure. Clin Investig. 1993;71(8 Suppl):S129-S133. View abstract.
  5. Rengo, F., Abete, P., Landino, P., Leosco, D., Covelluzzi, F., Vitale, D., Fedi, V., and Ferrara, N. Role of metabolic therapy in cardiovascular disease. Clin Investig. 1993;71(8 Suppl):S124-S128. View abstract.
  6. Lockwood, K., Moesgaard, S., Hanioka, T., and Folkers, K. Apparent partial remission of breast cancer in 'high risk' patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol.Aspects Med 1994;15 Suppl:s231-s240. View abstract.
  7. Iarussi, D., Auricchio, U., Agretto, A., Murano, A., Giuliano, M., Casale, F., Indolfi, P., and Iacono, A. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non- Hodgkin lymphoma. Mol.Aspects Med 1994;15 Suppl:s207-s212. View abstract.
  8. Morisco, C., Nappi, A., Argenziano, L., Sarno, D., Fonatana, D., Imbriaco, M., Nicolai, E., Romano, M., Rosiello, G., and Cuocolo, A. Noninvasive evaluation of cardiac hemodynamics during exercise in patients with chronic heart failure: effects of short-term coenzyme Q10 treatment. Mol.Aspects Med 1994;15 Suppl:s155-s163. View abstract.
  9. Kuklinski, B., Weissenbacher, E., and Fahnrich, A. Coenzyme Q10 and antioxidants in acute myocardial infarction. Mol.Aspects Med 1994;15 Suppl:s143-s147. View abstract.
  10. Tsubaki, K., Horiuchi, A., Kitani, T., Taniguchi, N., Masaoka, T., Shibata, H., Yonezawa, T., Tsubakio, T., Kawagoe, H., Shinohara, Y., and . [Investigation of the preventive effect of CoQ10 against the side- effects of anthracycline antineoplastic agents]. Gan To Kagaku Ryoho 1984;11:1420-1427. View abstract.
  11. Okuma, K., Furuta, I., and Ota, K. [Protective effect of coenzyme Q10 in cardiotoxicity induced by adriamycin]. Gan To Kagaku Ryoho 1984;11:502-508. View abstract.
  12. Matsumura, T., Saji, S., Nakamura, R., and Folkers, K. Evidence for enhanced treatment of periodontal disease by therapy with coenzyme Q. Int J Vitam.Nutr Res 1973;43:537-548. View abstract.
  13. Langsjoen, P. H., Vadhanavikit, S., and Folkers, K. Effective treatment with coenzyme Q10 of patients with chronic myocardial disease. Drugs Exp.Clin Res 1985;11:577-579. View abstract.
  14. Bresolin, N., Bet, L., Binda, A., Moggio, M., Comi, G., Nador, F., Ferrante, C., Carenzi, A., and Scarlato, G. Clinical and biochemical correlations in mitochondrial myopathies treated with coenzyme Q10. Neurology 1988;38:892-899. View abstract.
  15. Deichmann, R. E., Lavie, C. J., and Dornelles, A. C. Impact of coenzyme Q-10 on parameters of cardiorespiratory fitness and muscle performance in older athletes taking statins. Phys.Sportsmed. 2012;40:88-95. View abstract.
  16. Fotino, A. D., Thompson-Paul, A. M., and Bazzano, L. A. Effect of coenzyme Q supplementation on heart failure: a meta-analysis. Am.J.Clin.Nutr. 2013;97:268-275. View abstract.
  17. Fogagnolo, P., Sacchi, M., Ceresara, G., Paderni, R., Lapadula, P., Orzalesi, N., and Rossetti, L. The effects of topical coenzyme Q10 and vitamin E D-alpha-tocopheryl polyethylene glycol 1000 succinate after cataract surgery: a clinical and in vivo confocal study. Ophthalmologica 2013;229:26-31. View abstract.
  18. Bloomer, R. J., Canale, R. E., McCarthy, C. G., and Farney, T. M. Impact of oral ubiquinol on blood oxidative stress and exercise performance. Oxid.Med.Cell Longev. 2012;2012:465020. View abstract.
  19. Mortensen, S. A., Vadhanavikit, S., Muratsu, K., and Folkers, K. Coenzyme Q10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure. Int J Tissue React. 1990;12:155-162. View abstract.
  20. Bookstaver, D. A., Burkhalter, N. A., and Hatzigeorgiou, C. Effect of coenzyme Q10 supplementation on statin-induced myalgias. Am.J.Cardiol. 8-15-2012;110:526-529. View abstract.
  21. Hernandez-Ojeda, J., Cardona-Munoz, E. G., Roman-Pintos, L. M., Troyo-Sanroman, R., Ortiz-Lazareno, P. C., Cardenas-Meza, M. A., Pascoe-Gonzalez, S., and Miranda-Diaz, A. G. The effect of ubiquinone in diabetic polyneuropathy: a randomized double-blind placebo-controlled study. J.Diabetes Complications 2012;26:352-358. View abstract.
  22. Liu, J., Wang, L., Zhan, S. Y., and Xia, Y. Coenzyme Q10 for Parkinson's disease. Cochrane Database Syst.Rev. 2011;:CD008150. View abstract.
  23. Young, J. M., Florkowski, C. M., Molyneux, S. L., McEwan, R. G., Frampton, C. M., Nicholls, M. G., Scott, R. S., and George, P. M. A randomized, double-blind, placebo-controlled crossover study of coenzyme Q10 therapy in hypertensive patients with the metabolic syndrome. Am J Hypertens. 2012;25:261-270. View abstract.
  24. Sieswerda, E., van Dalen, E. C., Postma, A., Cheuk, D. K., Caron, H. N., and Kremer, L. C. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cochrane Database Syst.Rev. 2011;:CD008011. View abstract.
  25. Slater, S. K., Nelson, T. D., Kabbouche, M. A., Lecates, S. L., Horn, P., Segers, A., Manning, P., Powers, S. W., and Hershey, A. D. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia 2011;31:897-905. View abstract.
  26. Cooney, R. V., Dai, Q., Gao, Y. T., Chow, W. H., Franke, A. A., Shu, X. O., Li, H., Ji, B., Cai, Q., Chai, W., and Zheng, W. Low plasma coenzyme Q levels and breast cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev. 2011;20:1124-1130. View abstract.
  27. Ryo, K., Ito, A., Takatori, R., Tai, Y., Arikawa, K., Seido, T., Yamada, T., Shinpo, K., Tamaki, Y., Fujii, K., Yamamoto, Y., and Saito, I. Effects of coenzyme Q10 on salivary secretion. Clin Biochem 2011;44(8-9):669-674. View abstract.
  28. Nadjarzadeh, A., Sadeghi, M. R., Amirjannati, N., Vafa, M. R., Motevalian, S. A., Gohari, M. R., Akhondi, M. A., Yavari, P., and Shidfar, F. Coenzyme Q10 improves seminal oxidative defense but does not affect on semen parameters in idiopathic oligoasthenoteratozoospermia: a randomized double-blind, placebo controlled trial. J Endocrinol.Invest 2011;34:e224-e228. View abstract.
  29. Ahn, J. H., Yoo, M. H., Lee, H. J., Chung, J. W., and Yoon, T. H. Coenzyme Q10 in combination with steroid therapy for treatment of sudden sensorineural hearing loss: a controlled prospective study. Clin Otolaryngol. 2010;35:486-489. View abstract.
  30. Guastini, L., Mora, R., Dellepiane, M., Santomauro, V., Giorgio, M., and Salami, A. Water-soluble coenzyme Q10 formulation in presbycusis: long-term effects. Acta Otolaryngol. 2011;131:512-517. View abstract.
  31. Safarinejad, M. R. Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease: a double-blind, placebo-controlled randomized study. Int J Impot.Res 2010;22:298-309. View abstract.
  32. Pineda, M., Montero, R., Aracil, A., O'Callaghan, M. M., Mas, A., Espinos, C., Martinez-Rubio, D., Palau, F., Navas, P., Briones, P., and Artuch, R. Coenzyme Q-responsive ataxia: 2-year-treatment follow-up. Mov Disord. 7-15-2010;25:1262-1268. View abstract.
  33. Gane, E. J., Weilert, F., Orr, D. W., Keogh, G. F., Gibson, M., Lockhart, M. M., Frampton, C. M., Taylor, K. M., Smith, R. A., and Murphy, M. P. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int. 2010;30:1019-1026. View abstract.
  34. Salami, A., Mora, R., Dellepiane, M., Manini, G., Santomauro, V., Barettini, L., and Guastini, L. Water-soluble coenzyme Q10 formulation (Q-TER((R))) in the treatment of presbycusis. Acta Otolaryngol. 2010;130:1154-1162. View abstract.
  35. Ozaki, A., Muromachi, A., Sumi, M., Sakai, Y., Morishita, K., and Okamoto, T. Emulsification of coenzyme Q10 using gum arabic increases bioavailability in rats and human and improves food-processing suitability. J Nutr Sci Vitaminol.(Tokyo) 2010;56:41-47. View abstract.
  36. Hertz, N. and Lister, R. E. Improved survival in patients with end-stage cancer treated with coenzyme Q and other antioxidants: a pilot study. J Int.Med Res 2009;37:1961-1971. View abstract.
  37. Fetoni, A. R., Garzaro, M., Ralli, M., Landolfo, V., Sensini, M., Pecorari, G., Mordente, A., Paludetti, G., and Giordano, C. The monitoring role of otoacoustic emissions and oxidative stress markers in the protective effects of antioxidant administration in noise-exposed subjects: a pilot study. Med Sci Monit. 2009;15:R1-R8. View abstract.
  38. Kaufmann, P., Thompson, J. L., Levy, G., Buchsbaum, R., Shefner, J., Krivickas, L. S., Katz, J., Rollins, Y., Barohn, R. J., Jackson, C. E., Tiryaki, E., Lomen-Hoerth, C., Armon, C., Tandan, R., Rudnicki, S. A., Rezania, K., Sufit, R., Pestronk, A., Novella, S. P., Heiman-Patterson, T., Kasarskis, E. J., Pioro, E. P., Montes, J., Arbing, R., Vecchio, D., Barsdorf, A., Mitsumoto, H., and Levin, B. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009;66:235-244. View abstract.
  39. Mori, T. A., Burke, V., Puddey, I., Irish, A., Cowpland, C. A., Beilin, L., Dogra, G., and Watts, G. F. The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial. J Hypertens. 2009;27:1863-1872. View abstract.
  40. Gokbel, H., Gul, I., Belviranl, M., and Okudan, N. The effects of coenzyme Q10 supplementation on performance during repeated bouts of supramaximal exercise in sedentary men. J Strength Cond.Res 2010;24:97-102. View abstract.
  41. Scarlato, G., Bresolin, N., Moroni, I., Doriguzzi, C., Castelli, E., Comi, G., Angelini, C., and Carenzi, A. Multicenter trial with ubidecarenone: treatment of 44 patients with mitochondrial myopathies. Rev Neurol.(Paris) 1991;147(6-7):542-548. View abstract.
  42. Inui, M., Ooe, M., Fujii, K., Matsunaka, H., Yoshida, M., and Ichihashi, M. Mechanisms of inhibitory effects of CoQ10 on UVB-induced wrinkle formation in vitro and in vivo. Biofactors 2008;32(1-4):237-243. View abstract.
  43. Adarsh, K., Kaur, H., and Mohan, V. Coenzyme Q10 (CoQ10) in isolated diastolic heart failure in hypertrophic cardiomyopathy (HCM). Biofactors 2008;32(1-4):145-149. View abstract.
  44. Cooper, J. M., Korlipara, L. V., Hart, P. E., Bradley, J. L., and Schapira, A. H. Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur.J Neurol. 2008;15:1371-1379. View abstract.
  45. Molyneux, S. L., Florkowski, C. M., George, P. M., Pilbrow, A. P., Frampton, C. M., Lever, M., and Richards, A. M. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll.Cardiol. 10-28-2008;52:1435-1441. View abstract.
  46. Skough, K., Krossen, C., Heiwe, S., Theorell, H., and Borg, K. Effects of resistance training in combination with coenzyme Q10 supplementation in patients with post-polio: a pilot study. J Rehabil.Med 2008;40:773-775. View abstract.
  47. Keogh, A., Fenton, S., Leslie, C., Aboyoun, C., Macdonald, P., Zhao, Y. C., Bailey, M., and Rosenfeldt, F. Randomised double-blind, placebo-controlled trial of coenzyme Q, therapy in class II and III systolic heart failure. Heart Lung Circ. 2003;12:135-141. View abstract.
  48. Sunamori, M., Tanaka, H., Maruyama, T., Sultan, I., Sakamoto, T., and Suzuki, A. Clinical experience of coenzyme Q10 to enhance intraoperative myocardial protection in coronary artery revascularization. Cardiovasc.Drugs Ther 1991;5 Suppl 2:297-300. View abstract.
  49. Chew, G. T., Watts, G. F., Davis, T. M., Stuckey, B. G., Beilin, L. J., Thompson, P. L., Burke, V., and Currie, P. J. Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction. Diabetes Care 2008;31:1502-1509. View abstract.
  50. Mizuno, K., Tanaka, M., Nozaki, S., Mizuma, H., Ataka, S., Tahara, T., Sugino, T., Shirai, T., Kajimoto, Y., Kuratsune, H., Kajimoto, O., and Watanabe, Y. Antifatigue effects of coenzyme Q10 during physical fatigue. Nutrition 2008;24:293-299. View abstract.
  51. Eiholzer, U., Meinhardt, U., Rousson, V., Petrovic, N., Schlumpf, M., and l'Allemand, D. Developmental profiles in young children with Prader-Labhart-Willi syndrome: effects of weight and therapy with growth hormone or coenzyme Q10. Am J Med Genet.A 4-1-2008;146:873-880. View abstract.
  52. Rosenfeldt, F. L., Haas, S. J., Krum, H., Hadj, A., Ng, K., Leong, J. Y., and Watts, G. F. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum.Hypertens. 2007;21:297-306. View abstract.
  53. Sander, S., Coleman, C. I., Patel, A. A., Kluger, J., and White, C. M. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail. 2006;12:464-472. View abstract.
  54. Belardinelli, R., Mucaj, A., Lacalaprice, F., Solenghi, M., Seddaiu, G., Principi, F., Tiano, L., and Littarru, G. P. Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J 2006;27:2675-2681. View abstract.
  55. Gvozdjakova, A., Kucharska, J., Bartkovjakova, M., Gazdikova, K., and Gazdik, F. E. Coenzyme Q10 supplementation reduces corticosteroids dosage in patients with bronchial asthma. Biofactors 2005;25(1-4):235-240. View abstract.
  56. Belardinelli, R., Mucaj, A., Lacalaprice, F., Solenghi, M., Principi, F., Tiano, L., and Littarru, G. P. Coenzyme Q10 improves contractility of dysfunctional myocardium in chronic heart failure. Biofactors 2005;25(1-4):137-145. View abstract.
  57. Rusciani, L., Proietti, I., Rusciani, A., Paradisi, A., Sbordoni, G., Alfano, C., Panunzi, S., De Gaetano, A., and Lippa, S. Low plasma coenzyme Q10 levels as an independent prognostic factor for melanoma progression. J Am Acad Dermatol 2006;54:234-241. View abstract.
  58. Feher, J., Kovacs, B., Kovacs, I., Schveoller, M., Papale, A., and Balacco, Gabrieli C. Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10. Ophthalmologica 2005;219:154-166. View abstract.
  59. Hart, P. E., Lodi, R., Rajagopalan, B., Bradley, J. L., Crilley, J. G., Turner, C., Blamire, A. M., Manners, D., Styles, P., Schapira, A. H., and Cooper, J. M. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch.Neurol. 2005;62:621-626. View abstract.
  60. Hoenjet, K. M., Dagnelie, P. C., Delaere, K. P., Wijckmans, N. E., Zambon, J. V., and Oosterhof, G. O. Effect of a nutritional supplement containing vitamin E, selenium, vitamin c and coenzyme Q10 on serum PSA in patients with hormonally untreated carcinoma of the prostate: a randomised placebo-controlled study. Eur Urol 2005;47:433-439. View abstract.
  61. Reid, M. S., Casadonte, P., Baker, S., Sanfilipo, M., Braunstein, D., Hitzemann, R., Montgomery, A., Majewska, D., Robinson, J., and Rotrosen, J. A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence. Addiction 2005;100 Suppl 1:43-57. View abstract.
  62. Rosenfeldt, F., Marasco, S., Lyon, W., Wowk, M., Sheeran, F., Bailey, M., Esmore, D., Davis, B., Pick, A., Rabinov, M., Smith, J., Nagley, P., and Pepe, S. Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue. J Thorac.Cardiovasc.Surg. 2005;129:25-32. View abstract.
  63. Damian, M. S., Ellenberg, D., Gildemeister, R., Lauermann, J., Simonis, G., Sauter, W., and Georgi, C. Coenzyme Q10 combined with mild hypothermia after cardiac arrest: a preliminary study. Circulation 11-9-2004;110:3011-3016. View abstract.
  64. Rosenfeldt, F., Hilton, D., Pepe, S., and Krum, H. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. Biofactors 2003;18(1-4):91-100. View abstract.
  65. Snider, I. P., Bazzarre, T. L., Murdoch, S. D., and Goldfarb, A. Effects of coenzyme athletic performance system as an ergogenic aid on endurance performance to exhaustion. Int J Sport Nutr 1992;2:272-286. View abstract.
  66. Munkholm, H., Hansen, H. H., and Rasmussen, K. Coenzyme Q10 treatment in serious heart failure. Biofactors 1999;9(2-4):285-289. View abstract.
  67. Marazzi, G., Cacciotti, L., Pelliccia, F., Iaia, L., Volterrani, M., Caminiti, G., Sposato, B., Massaro, R., Grieco, F., and Rosano, G. Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Adv.Ther 2011;28:1105-1113. View abstract.
  68. Leong J. Y., van der Merwe J., Pepe S., Bailey M., Perkins A., Lymbury R., Esmore D., Marasco S., Rosenfeldt F. Perioperative metabolic therapy improves redox status and outcomes in cardiac surgery patients: a randomised trial. Heart Lung Circ 2010;19:584-591. View abstract.
  69. Galasko D. R., Peskind E., Clark C. M., Quinn J. F., Ringman J. M., Jicha G. A., Cotman C., Cottrell B., Montine T. J., Thomas R. G., Aisen P. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 2012;69:836-841. View abstract.
  70. Lister RE. An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo biloba extract in fibromyalgia syndrome. J Int Med Res 2002;30:195-9. View abstract.
  71. Cordero MD, Moreno-Fernandez AM, deMiguel M, et al. Coenzyme Q10 distribution in blood is altered in patients with fibromyalgia. Clin Biochem 2009;42:732-5. View abstract.
  72. Lee YJ, Cho WJ, Kim JK, Lee DC. Effects of coenzyme Q10 on arterial stiffness, metabolic parameters, and fatigue in obese subjects: a double-blind randomized controlled study. J Med Food 2011;14:386-90. View abstract.
  73. Boles RG, Lovett-Barr MR, Preston A, et al. Treatment of cyclic vomiting syndrome with co-enzyme Q10 and amitriptyline, a retrospective study. BMC Neurol 2010;10:10. View abstract.
  74. Ho MJ, Bellusci A, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension (review). Cochrane Database Syst Rev 2009;:CD007435. View abstract.
  75. Yamagami T, Takagi M, Akagami H, et al. Effect of coenzyme Q10 on essential hypertension, a double blind controlled study. In: Folkers KA, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q, Vol. 5. Amsterdam: Elsevier Science Publications, 1986:337-43.
  76. Digiesi V, Cantini F, Oradei A, et al. Coenzyme Q10 in essential hypertension. Mol Aspects Med 1994;15 Suppl:s257-63. View abstract.
  77. Safarinejad MR. Efficacy of coenzyme Q-10 on semen parameters, sperm function and reproductive hormones in infertile men. J Urol 2009;182:237-48. View abstract.
  78. Teran E, Hernandez I, Nieto B, et al. Coenzyme Q10 supplementation during pregnancy reduces the risk of pre-eclampsia. Int J Gynaecol Obstet 2009;105:43-5. View abstract.
  79. Marcoff L, Thompson, PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007;49:2231-7. View abstract.
  80. Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007;99:1409-12. View abstract.
  81. Storch A, Jost WH, Vieregge P, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson disease. Arch Neurol 2007;64:938-44. View abstract.
  82. Hershey AD, Powers SW, Vockell AB, et al. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent Migraine. Headache 2007;47:73-80. View abstract.
  83. The NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007;68:20-8. View abstract.
  84. Berthold HK, Naini A, Di Mauro S, et al. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Saf 2006;29:703-12. View abstract.
  85. Zhou Q, Chowbay B. Effect of coenzyme Q10 on the disposition of doxorubicin in rats. Eur J Drug Metab Pharmacokinet 2002;27:185-92. View abstract.
  86. Eaton S, Skinner R, Hale JP, et al. Plasma coenzyme Q in children and adolescents undergoing doxorubicin therapy. Clin Chim Acta 2000;302:1-9. View abstract.
  87. Soongswang J, Sangtawesin C, Durongpisitkul K, et al. The effect of coenzyme Q10 on idiopathic chronic dilated cardiomyopathy in children. Pediatr Cardiol 2005;26:361-6. View abstract.
  88. Elshershari H, Ozer S, Ozkutlu S, Ozme S. Potential usefulness of coenzyme Q10 in the treatment of idiopathic dilated cardiomyopathy in children. Int J Cardiol 2003;88:101-2. View abstract.
  89. Berman M, Erman A, Ben-Gal T, et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clin Cardiol 2004;27:295–9. View abstract.
  90. Balercia G, Mosca F, Mantero F, et al. Coenzyme Q10 supplementation in infertile men with idiopathic asthenozoospermia: an open, uncontrolled pilot study. Fertil Steril 2004;81:93-8. View abstract.
  91. Rundek T, Naini A, Sacco R, et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol 2004;61:889-92.. View abstract.
  92. Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial. Thromb Haemost 2002;87:1075-6. View abstract.
  93. Taggart DP, Jenkins M, Hooper J, et al. Effects of short-term supplementation with coenzyme Q10 on myocardial protection during cardiac operations. Ann Thorac Surg 1996;61:829-33. View abstract.
  94. Chello M, Mastroroberto P, Romano R, et al. Protection by coenzyme Q10 from myocardial reperfusion injury during coronary artery bypass grafting. Ann Thorac Surg 1994;58:1427-32. View abstract.
  95. Chello M, Mastroroberto P, Romano R, et al. Protection by coenzyme Q10 of tissue reperfusion injury during abdominal aortic cross-clamping. J Cardiovasc Surg (Torino) 1996;37:229-35. View abstract.
  96. Kim WS, Kim MM, Choi HJ, et al. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 2001;19:81-3. View abstract.
  97. Thibault A, Samid D, Tompkins AC, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996;2:483-91. View abstract.
  98. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90. View abstract.
  99. Welch KM. Current opinions in headache pathogenesis: introduction and synthesis. Curr Opin Neurol 1998;11:193-7. View abstract.
  100. Lee CK, Pugh TD, Klopp RG, et al. The impact of alpha-lipoic acid, coenzyme Q10 and caloric restriction on life span and gene expression patterns in mice. Free Radic Biol Med 2004;36:1043-57. View abstract.
  101. Ishii N, Senoo-Matsuda N, Miyake K, et al. Coenzyme Q10 can prolong C. elegans lifespan by lowering oxidative stress. Mech Ageing Dev 2004;125:41-6. View abstract.
  102. Tran MT, Mitchell TM, Kennedy DT, Giles JT. Role of coenzyme Q10 in chronic heart failure, angina, and hypertension. Pharmacotherapy 2001;21:797-806. View abstract.
  103. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for the clinical use of dietary supplements and nutraceuticals. Endocr Pract 2003;9:417-70. View abstract.
  104. Turunen M, Olsson J, Dallner G. Metabolism and function of coenzyme Q. Biochim Biophys Acta 2004;1660:171-99. View abstract.
  105. Playford DA, Watts GF, Croft KD, Burke V. Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. Atherosclerosis 2003;168:169-79. View abstract.
  106. FDA. List of Orphan Designations and Approvals. (Accessed 19 June 2004).
  107. Sandor PS, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial. Neurology 2005;64:713-5. View abstract.
  108. Berbel-Garcia A, Barbera-Farre JR, Etessam JP, ET AL. Coenzyme Q 10 improves lactic acidosis, strokelike episodes, and epilepsy in a patient with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes). Clin Neuropharmacol 2004;27:187-91. View abstract.
  109. Joshi SS, Sawant SV, Shedge A, Halpner AD. Comparative bioavailability of two novel coenzyme Q10 preparations in humans. Int J Clin Pharmacol Ther 2003;41:42-8. View abstract.
  110. Porterfield LM. Why did the response to warfarin change? RN 2000;63:107. View abstract.
  111. Langsjoen PH, Langsjoen A, Willis R, Folkers K. Treatment of hypertrophic cardiomyopathy with coenzyme Q10. Mol Aspects Med 1997;18 Suppl:S145-51. View abstract.
  112. Singh RB, Neki NS, Kartikey K, et al. Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. Mol Cell Biochem 2003;246:75-82. View abstract.
  113. Hodgson JM, Watts GF, Playford DA, et al. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 2002;56:1137-42.. View abstract.
  114. Bertelli A, Cerrati A, Giovannini L, et al. Protective action of L-carnitine and coenzyme Q10 against hepatic triglyceride infiltration induced by hyperbaric oxygen and ethanol. Drugs Exp Clin Res 1993;19:65-8.. View abstract.
  115. Kishi T, Makino K, Okamoto T, et al. Inhibition of myocardial respiration by psychotherapeutic drugs and prevention by coenzyme Q. In: Yamamura Y, Folkers K, Ito Y (eds). Biomedical and clinical aspects of coenzyme Q. Amsterdam: Elsevier/North-Holland Biomedical Press 1980;2:139-54.
  116. Pepping J. Coenzyme Q10. Am J Health-Syst Pharm 1999;56:519-21. View abstract.
  117. Ferrante RJ, Andreassen OA, Dedeoglu A, et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 2002;22:1592-9.. View abstract.
  118. The Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001;57:397-404. View abstract.
  119. Shults CW, Beal MF, Fontaine D, et al. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology 1998;50:793-5. View abstract.
  120. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-50. View abstract.
  121. Wilkinson EG, Arnold RM, Folkers K. Bioenergetics in clinical medicine. VI. Adjunctive treatment of periodontal disease with coenzyme Q10. Res Commun Chem Pathol Pharmacol 1976;14:715-9. View abstract.
  122. Wilkinson EG, Arnold RM, Folkers K, et al. Bioenergetics in clinical medicine. II. Adjunctive treatment with coenzyme Q in periodontal therapy. Res Commun Chem Pathol Pharmacol 1975;12:111-23. View abstract.
  123. Iwamoto Y, Nakamura R, Folkers K, Morrison RF. Study of periodontal disease and coenzyme Q. Res Commun Chem Pathol Pharmacol 1975;11:265-71. View abstract.
  124. Bleske BE, Willis RA, Anthony M, et al. The effect of pravastatin and atorvastatin on coenzyme Q10. Am Heart J 2001;142:E2. View abstract.
  125. de Rijke YB, Bredie SJ, Demacker PN, et al. The redox status of coenzyme Q10 in total LDL as an indicator of in vivo oxidative modification. Studies on subjects with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1997;17:127-33. View abstract.
  126. Crane FL. Biochemical functions of coenzyme Q10. J Am Coll Nutr 2001;20:591-8. View abstract.
  127. Musumeci O, Naini A, Slonim AE, et al. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology 2001;56:849-55. View abstract.
  128. Bonetti A, Solito F, Carmosino G, et al. Effect of ubidecarenone oral treatment on aerobic power in middle-aged trained subjects. J Sports Med Phys Fitness 2000;40:51-7. View abstract.
  129. Mortensen SA. Coenzyme Q10 as an adjunctive therapy in patients with congestive heart failure. JACC 2000;36:304-5. View abstract.
  130. Soja AM, Mortensen SA. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol Aspects Med 1997;18:S159-68. View abstract.
  131. Lonnrot K, Porsti I, Alho H, et al. Control of arterial tone after long-term coenzyme Q10 supplementation in senescent rats. Br J Pharmacol 1998;124:1500-6. View abstract.
  132. Burke BE, Neuenschwander R, Olson RD. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. South Med J 2001;94:1112-7. View abstract.
  133. Bresolin N, Doriguzzi C, Ponzetto C, et al. Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial. J Neurol Sci 1990;100:70-8. View abstract.
  134. Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur Neurol 1997;37:212-8. View abstract.
  135. Boitier E, Degoul F, Desguerre I, et al. A case of mitochondrial encephalomyopathy associated with a muscle coenzyme Q10 deficiency. J Neurol Sci 1998;156:41-6. View abstract.
  136. Sobreira C, Hirano M, Shanske S, et al. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. Neurology 1997;48:1238-43. View abstract.
  137. Chan A, Reichmann H, Kogel A, et al. Metabolic changes in patients with mitochondrial myopathies and effects of coenzyme Q10 therapy. J Neurol 1998;245:681-5. View abstract.
  138. Rozen TD, Oshinsky ML, Gebeline CA, et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 2002;22:137-41. View abstract.
  139. Elsayed NM, Bendich A. Dietary antioxidants: potential effects on oxidative products in cigarette smoke. Nutr Res 2001;21:551-67.
  140. Pizzorno JE, Murray MT, eds. Textbook of Natural Medicine. 2nd ed. New York: Churchill Livingston, 1999.
  141. Baggio E, Gandini R, Plauncher AC, et al. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol Aspects Med 1994;15 Suppl:S287-94. View abstract.
  142. Hofman-Bang C, Rehnqvist N, Swedberg K, et al. Coenzyme Q10 as an adjunctive treatment of congestive heart failure. J Card Fail 1995;1:101-7. View abstract.
  143. Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: A long-term, multicenter, randomized study. Clin Investig 1993;71:S134-6. View abstract.
  144. Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160:3226-7. View abstract.
  145. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm 2000;57:1221-7. View abstract.
  146. Langsjoen PH, Langsjoen PH, Folkers K. Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1990;65:521-3. View abstract.
  147. Permanetter B, Rossy W, Klein G, et al. Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy. Eur Heart J 1992;13:1528-33. View abstract.
  148. Watson PS, Scalia GM, Galbraith A, et al. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol 1999;33:1549-52. View abstract.
  149. Azuma J, Sawamura A, Awata N. Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ J 1992;56:95-9. View abstract.
  150. Lund EL, Quistorff B, Spang-Thomsen M, Kristjansen PE. Effect of radiation therapy on small-cell lung cancer is reduced by ubiquinone intake. Folia Microbiol (Praha) 1998;43:505-6. View abstract.
  151. Portakal O, Ozkaya O, Erden Inal M, et al. Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin Biochem 2000;33:279-84. View abstract.
  152. Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med 2000;132:636-40. View abstract.
  153. Jolliet P, Simon N, Barre J, et al. Plasma coenzyme Q10 concentrations in breast cancer: prognosis and therapeutic consequences. Int J Clin Pharmacol Ther 1998;36:506-9. View abstract.
  154. Hanaki Y, Sugiyama S, Ozawa T, et al. Coenzyme Q10 and coronary artery disease. Clin Investig 1993;71:112-5. View abstract.
  155. Watts GF, Castelluccio C, Rice-Evans C, et al. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 1993;46:1055-7. View abstract.
  156. Bargossi AM, Grossi G, Fiorella PL, et al. Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors. Mol Aspects Med 1994;15:187-93. View abstract.
  157. De Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs and mitochondrial function: Effects of HMG-CoA Reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996;42:333-7. View abstract.
  158. Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: A double blind, placebo-controlled study. J Clin Pharmacol 1993;33:226-9. View abstract.
  159. Mortensen SA, Leth A, Agner E, et al. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 1997;18:S137-44. View abstract.
  160. Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 1990;87:8931-4. View abstract.
  161. Lockwood K, Moesgaard S, Folkers K. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Commun 1994;199:1504-8. View abstract.
  162. Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun 1995;212:172-7. View abstract.
  163. Bertelli A, Ronca G. Carnitine and coenzyme Q10: biochemical properties and functions, synergism and complementary action. Int J Tissue React 1990;12:183-6. View abstract.
  164. Fuke C, Krikorian SA, Couris RR. Coenzyme Q10: A review of essential functions and clinical trials. US Pharm 2000;25:28-41.
  165. Kishi H, Kishi T, Folkers K. Bioenergetics in clinical medicine. III. Inhibition of coenzyme Q10 enzymes by clinically used anti-hypertensive drugs. Res Commun Chem Pathol Pharmacol 1975;12:533-40. View abstract.
  166. Kishi T, Watanabe T, Folkers K. Bioenergetics in clinical medicine. XV. Inhibition of coenzyme Q10 enzymes by clinically used adrenergic blockers of B-receptors. Res Commun Chem Pathol Pharmacol 1977;17:157-64. View abstract.
  167. Laaksonen R, Jokelainen K, Sahi T, et al. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 1995;57:62-6. View abstract.
  168. Rotig A, Appelkvist EL, Geromel V, et al. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 2000;356:391-5. View abstract.
  169. Singh RB, Niaz MA, Rastogi SS, et al. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. J Hum Hypertens 1999;13:203-8. View abstract.
  170. Greenberg S, Frishman WH. Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol 1990;30:596-608. View abstract.
  171. Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;334:1372-3. View abstract.
  172. Folkers K, Simonsen R. Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochem Biophys Acta 1995;1271:281-6. View abstract.
  173. Andersen CB, Henriksen JE, Hother-Nielsen O, et al. The effect of coenzyme Q10 on blood glucose and insulin requirement in patients with insulin dependent diabetes mellitus. Mol Aspects Med 1997;18 Suppl:S307-9. View abstract.
  174. Suzuki S, Hinokio Y, Ohtomo M, et al. The effects of coenzyme Q10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A to G) mutation. Diabetologia 1998;41:584-8. View abstract.
  175. Folkers K, Langsjoen P, Nara Y, et al. Biochemical deficiencies of coenzyme Q10 in HIV-infection and exploratory treatment. Biochem Biophys Res Commun 1988;153:888-96. View abstract.
  176. Folkers K, Hanioka T, Xia LJ, et al. Coenzyme Q10 increases T4/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the AIDS related complex. Biochem Biophys Res Commun 1991;176:786-91. View abstract.
  177. Langsjoen P, Willis R, Folkers K. Treatment of essential hypertension with coenzyme Q10. Mol Aspects Med 1994;S265-72. View abstract.
  178. Kamikawa T, Kobayashi A, Yamashita T, et al. Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. Am J Cardiol 1985;56:247-51. View abstract.
  179. Weston SB, Zhou S, Weatherby RP, Robson SJ. Does exogenous coenzyme Q10 affect aerobic capacity in endurance athletes? Int J Sport Nutr 1997;7:197-206. View abstract.
  180. Malm C, Svensson M, Ekblom B, et al. Effects of ubiquinone-10 supplementation and high intensity training on physical performance in humans. Acta Physiol Scand 1997;161:379-84. View abstract.
  181. Watts TLP. Coenzyme Q10 and periodontal treatment: is there any beneficial effect? Br Dent J 1995;178:209-13. View abstract.
  182. Hanioka T, Tanaka M, Ojima M, et al. Effect of topical application of coenzyme Q10 on adult periodontitis. Molec Aspects Med 1994;15:S241-8. View abstract.
  183. Feigin A, Kieburtz K, Como P, et al. Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov Disord 1996;11:321-3. View abstract.
  184. Robbers JE, Tyler VE. Tyler's Herbs of Choice: The Therapeutic Use of Phytomedicinals. New York, NY: The Haworth Herbal Press, 1999.
  185. Eriksson JG, Forsen TJ, Mortensen SA, Rohde M. The effect of coenzyme Q10 administration on metabolic control in patients with type 2 diabetes mellitus. Biofactors 1999;9:315-8. View abstract.
  186. Weis M, Mortensen SA, Rassing MR, et al. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. Mol Aspects Med 1994;15:s273-80. View abstract.
  187. Henriksen JE, Andersen CB, Hother-Nielsen O, et al. Impact of ubiquinone (coenzyme Q10) treatment on glycaemic control, insulin requirement and well-being in patients with Type 1 diabetes mellitus. Diabet Med 1999;16:312-8. View abstract.
  188. Nagao T, Ibayashi S, Fujii K, et al. Treatment of warfarin-induced hair loss with ubidecarenone. Lancet 1995;346:1104-5. View abstract.
Show more references
Show fewer references
Last reviewed - 10/20/2014

Page last updated: 10 December 2014